Bioprocessing Gets Smarter With PatroLab

WuXi Biologics unveils PatroLab, merging Raman analytics and AI to speed biologics manufacturing and sharpen quality control

18 Mar 2026

A shift in how biologics are made is beginning to take shape. WuXi Biologics introduced PatroLab in January 2026, positioning it as a digital twin platform that blends real-time monitoring with machine learning and predictive modeling to reshape development and production.

At its core is a Raman-based Process Analytical Technology system that continuously tracks more than 40 quality and performance indicators. Unlike traditional testing that pauses production, this system runs alongside the process, generating vastly richer data and offering a live window into the bioreactor.

That stream of data does more than inform, it acts. PatroLab builds virtual replicas of active bioprocesses, allowing teams to simulate outcomes, flag metabolic bottlenecks early, and troubleshoot issues during scale-up. Automated controls further reduce manual adjustments, helping stabilize batches and limit costly deviations in GMP environments.

The platform also aligns with regulatory momentum around real-time release testing from agencies like the FDA and EMA. By verifying quality throughout production instead of at the end, manufacturers can shorten timelines while maintaining tighter control over consistency and supply.

WuXi Biologics CEO Chris Chen describes the system as a turning point, bringing analytics, automation, and modeling into a single workflow. Integrated across the company’s digital backbone, PatroLab allows data to move seamlessly between development and manufacturing teams.

Biologics manufacturing has long struggled with the unpredictability of living systems. With its full-scale commercial deployment, PatroLab signals that AI-driven production is no longer theoretical but operational, setting a new pace for how biologics may be made in the years ahead.